Gamma-sarcoglycanopathy (LGMD 2C) with Del 525T mutation: Report of the first familial case in Niger by Moumouni, H et al.
 
Available online at http://ajol.info/index.php/ijbcs 
 






© 2011 International Formulae Group. All rights reserved.                                     
DOI :  http://dx.doi.org/10.4314/ijbcs.v5i6.1                                                                                                      
          Original Paper                                                     http://indexmedicus.afro.who.int 
 
Gamma-sarcoglycanopathy (LGMD 2C) with Del 525T mutation: report of 
the first familial case in Niger 
 
H. MOUMOUNI 1*, H. ASSADECK 1, S. GUIDA 1, B. S. SOUNA 1, R. ADAL 1,  
J. A. URTIZBEREA 2, F. LETURCQ 2 and R. B. DARBOUX 3 
 
1Faculté des Sciences de la Santé de Niamey, Laboratoire d’Histo-Embryologie, Neurologie, Radiologie 
Traumato-Orthopédie, Niger. 
2 Hôpital Marin de Handaye, France. 
3 Faculté des Sciences de la Santé de Cotonou, Laboratoire de Biologie Humaine, Benin. 





We are reporting a familial case of limb-girdle musc lar dystrophy (LGMD) upon 5 out of 6 siblings 
from parents showing no evidence of muscular dystrophy. The pedigree of the family up to five generations did 
not reveal any known case in the past even though consanguinity was reported. The clinical observations 
revealed wheelchair bound or difficulties for walking in all affected subjects, due to muscular dystrophy 
involving mainly the pelvic girdle. Creatine phosphoKinase (CK) was higher than normal values in both 
affected children and their parents. The scanning of thigh showed in all patients, an atrophy of the quadriceps 
with fatty conversion. Molecular analysis was carried out, first using western blot, which revealed gamma-
sacoglycan deficiency and second, by gene screening, which showed Del 525T mutation. This mutation is most 
widespread in arabo-berbères tribes including Touaregs. The present cases are in our knowledge the first 
reported in that part of Africa, south of Maghreb. We make a focus on histological and molecular bases of the 
LGMD.  
© 2011 International Formulae Group. All rights reserved. 
 




The myopathy referred mainly to 
Duchenne muscular dystrophy that was 
described by Duchenne in the middle of the 
19th century. This anomaly, recessive X-linked 
transmitted, affects exclusively men. 
Nowadays, many types of muscular diseases 
are known, based on their clinical and 
histopathological aspects, and the molecular 
bases of most of them are elucidated (Weiler 
and al., 1999; Leturcq and Kaplan, 2000; 
Urtizberea, 2001; Authier et al., 2008). A 
particular interest in investigating these 
pathologies was raised in developed countries 
around 1980 following the era of advances in 
molecular genetics (Gilchrist and al., 1988; 
Beckmann et al., 1991; Ginjaar et al., 2000; 
Sandona and Betto, 2009). It has been shown 
that  these pathologies derive from anomalies 
in proteins involved in muscle cell structures 
or functions. The contractibility of muscle 
cells is enabled by the presence of filaments 
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like actin, myosin, tropomyosin, and 
intermediate filaments, desmin particularly. 
They contain myoglobin, a pigment which 
fixes oxygen. Many other proteins are present 
in the cell plasma under the sarcolemma: 
integrins, spectrin, and the complex 
Dystrophine / Dystrophine Associated 
Glycoproteins (DAGs). The complex 
Dystrophine/DAGs is particularly involved in 
the occurrence of myopathies. The DAGs 
contain about 15 proteins which are linked to 
dystrophine. These proteins can be divided 
into 4 subgroups: dystroglycans, sarcoglycans, 
syntrophines and dystrobrevine. Although 
their functions are only partially known, it is 
clear that the complex dystrophine/DAGs 
participates in the stability of the sarcolemma. 
Moreover, deficiency in one element of this 
complex has been shown to alter all the 
system, then leading to fibber necrosis and 
fibrosis (Fanin et al., 1997; Leturcq and 
Kaplan, 2000; Authier et al., 2008; Sandona, 
and Betto, 2009). The diversity of the proteins 
that are involved in this phenomenon explains 
the numerous types of myopathies. The 
majority of myopathies are genetically 
transmitted, in variable ways: autosomic, X-
linked, recessive, dominant (Eymard et al., 
1997; Gilchrist et al., 1988; Bonne et al., 
1999; Speer et al., 1999). In spite important 
similarities, differences also exist in their 
clinical expression. Nevertheless, several 
probes exist now and are of great interests in 
molecular identification of the myopathies 
(Nigro et al., 1996; Leturcq and Kaplan, 2000; 
Khadilkar et al., 2009; Sandona and Betto, 
2009).   
In African countries such as Niger, 
muscular diseases are poorly known and are 
considered as a punishment from the nature. 
Here we report 5 cases of gamma 
sarcoglycanopathy in a consanguineous 
family of 6 siblings with clinical, 
histopathological and molecular confirmation. 
The objectives of the work were to enhance 
the knowledge of these muscular diseases as 
regards both clinical expression and molecular 
supports.  
 
MATERIALS AND METHODS  
The study population is a touareg 
family from Agadez (North of Niger), living 
in Niamey. Five of the 6 siblings were 
affected by a severe muscular dystrophy. The 
father and the mother were linked by a 
consanguineous marriage. They were 
respectively 47 and 38 years old and showed 
no clinical symptoms. The siblings included 3 
females (with a twin pair) and 3 males with 
ages ranging from 8 through 18 years (Figure 
1). We performed a full neurological 
examination followed by a general 
examination for the whole family. Then we 
used all clinical and laboratory investigation 
data after 10 years follow up. Laboratory 
investigations included cardiac 
ultrasonography, electrocardiogram, CT scan 
of the thigh and creatine phosphokinase (CK).  
A muscular biopsy was performed for 
western-blot using specific antibodies against 
dystrophine, dysferlin, calpain and 
sarcoglycans. The western blot test was 
followed by direct gene sequencings. During 
the study, regular home visits were organized 
to be in touch with the family and provide 
counselling and helps.  
 
RESULTS 
The pedigree allowed consanguinity 
rate evaluation (coefficient 0.0625). Only the 
hypothesis of autosomic recessive 
transmission can be accepted for this disease. 
The heterozygote of the subject V.6 has been 
added after the results of molecular biology 
test.  
Data provided by Bio-clinical 
investigations showed for all affected children 
an onset age around 9-10 years, an evidence 
of pelvic deficiency at age of 11 and 
wheelchair bounds at 13.  CK were high in all 
family members, even in the heterozygotes. 
Cardio-respiratory and intelligence 
evaluations were normal. CT scan of thigh in 
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affected subjects revealed atrophy of 
quadriceps with fatty conversion (Figure 2). 
The details of the main tests that were 
performed are summarized in Table 1. 
Deficits in calpain and dysferlin have 
been tested by Western-blot and gene 
sequencings they are also responsible for 
limb-girdle muscular dystrophies transmitted 
in autosomic recessive way.  
According to the touareg origin of the family, 
the delta 525T mutation that was known in 
arabo-berbères was first researched and 
confirmed in all the family members. Subjects 
V.1, 2, V.3, V.4 and V.5 were studied while 
the 2 parents and V.6 were heterozygote. 
The Western blot test revealed a 





Figure 1: Family’s pedigree on five generations. 
 














Subject V.5, 11 years old, showing pelvic deficit, s ill walking, but with difficulty. Note the 
importance of atrophy and fatty reconversion. 
 
 





Subject V.6, 8 years old, heterozygote, walks normally. Images are in normal limits. 
 
 





Figure 3: Evidence of gamma-sarcoglycan deficiency by western-blot test in subject V.3. 
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Protein gene Classification 
Type* 
Protein gene 
1A Myotilin 5q22 2A Calpain 15q15 
1B Lamin A/C 1q11 2B Dysferlin 2p13 
1C Caveolin 3p25 2C γ-sarcoglycan 13q12 
1D ? 6q23 2D α-sarcoglycan 17q12 
1E ? 7q 2E β-sarcoglycan 4q12 
* LGMD Type 1 = dominant    


















The pedigree analysis shows in spite of 
its singularity to assume autosomic recessive 
transmission, giving orientation towards the 
subgroup of myopathies to be tested. Pedigree 
analysis is not easy for genetic counselling 
even if we consider that the twins were 
monozygotes, the chance to observe 5 affected 
subjects in an offspring of 6 is less than 1/60 
000 for an expected risk of ¼. This pedigree 
gives support of targets for a wide research in 
the extended family by using these molecular 
probes. By matching these data and those 
provided by molecular analysis we confirmed 
to the parents that their last son (V.6) will not 
develop the full disease and we notify to them 
their ability to have unaffected offspring. The 
touareg origins of the family help us focus 
first on the Delta 525T mutation, which has 
been confirmed by gene screening (Ben 
Hamida et al., 1983; Fanin et al., 1997; 
Moreira et al., 1998; Leturcq and Kaplan, 
2000). Regarding the high rate of 
consanguinity found in the present study, 
further research should be extended to the 
large family. This will help in detecting 
heterozygotes and in preventing high-risk 
unions. The Delta 525T mutation was listed 
first as Delta 521T and is the most frequent 
cause of sarcoglycanopathy in patients of 
Maghreb origins. In Maghreb countries, it 
represents up to 50% of progressive muscular 
dystrophies in children versus 10 to 15% in 
Europe or United States. Our cases were the 
first to be reported in this part of Africa, in the 
south of Maghreb. Origins of Delta 525T 
mutation are yet discussed, but the high 
frequency in Maghreb allows the hypothesis 
of an existing link with arabo-berbers. The 
observation of cases in Mediterranean region 
(Libya, Jordan, Libanon, Saudi Arabia, 
Tunisia, etc.) and now in Niger can be 
explained by migration flows in this area 
(BenHamida et al., 1983; Urtasun et al., 1998; 
Ginjaar et al., 2000; Merlini et al, 2000; 
Khadilkar et al, 2009). The line between 
Touaregs and arabo-berbers is now well 
established; then it is not surprising to observe 
the Delta 525T mutation in this ethnic group. 
Paraclinic examinations revealed a rise 
of creatine phosphokinase (CK) in all 
members of the family but levels were < 1000 
U/L in heterozygotes. In addition, a muscular 
atrophy with fatty reconversion was clear in 
all homozygotes since the age of 8.  
Sarcoglycanopathies belong to the 
Limb Girdle Muscular dystrophies (LGMD) 
2D, 2E, 2F, and 2C in the nomenclature of 
European Neuromuscular Centre (ENMC) 
(Nigro et al., 1996; Sandona and Betto, 2009; 
Urtizberea, 2001). Their clinical expression is 
so similar that sometimes only 
immunochemistry or mutation analysis can 
help distinguishing them.  Myocardiopathy is 
usually rare in sarcoglycanopathies. 
Gamma-sarcoglycanopathy (LGMD 
2C) results from a molecular deficit in 
gamma-sarcoglycan, a protein of 25kD, 
encoded by a gene located on 13q12. Although 
cases have been reported in numerous 
countries, 2 ethnic groups are mainly 
involved: arabo-berbers and gipsy, which are 
known with important consanguineous 
marriage. In arabo-berbers the mutation is 
Delta 525T and C283Y in gipsy. Seven other 
mutations were reported, involving the same 
gene (Fanin et al., 1997; Urtasun et al., 1998; 
Merlini et al., 2000).  
Myopathies resulting from anomalies 
of other proteins have been reported: (calpain, 
telethonin, dysferlin, myotilin, lamin, 
caveolin, etc.) (Liu et al., 1998; Mc Nally et 
al., 1990; Baghdiguian et al., 1999; Bonne et 
al., 1999; Hauser et al., 2000). Other 
myopathies rise from more complex 
disturbances e.g. a repetition of triplets 
(Steinert myopathy) or as the consequence of 
abnormal unknown proteins as reported by 
Speer et al. (1999) in Landouzy-Déjerine, 
LGMD 1D, LGMD 1E, etc. (Table 2). 
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